Epilepsy with Myoclonic-Atonic Seizures Overview

Save information for later
Sign Up

Learn About Epilepsy with Myoclonic-Atonic Seizures

What is the definition of Epilepsy with Myoclonic-Atonic Seizures?
Epilepsy with myoclonic-atonic seizures is a rare epilepsy syndrome of early childhood. It is characterized by seizures of many different types, most often myoclonic-atonic, astatic, or generalized tonic-clonic seizures. Seizures can be followed by drop attacks, which can lead to falls and injuries. Absence seizures may occur. People with the condition may experience several seizures each day. The epilepsy may result in a delay or regression of skills. Autistic features and ataxic (poorly controlled) movements have been reported in some cases. Changes in the SCN1A, SCN1B, GABRG2, CHD2, and SLC6A1 genes can cause or contribute to Epilepsy with myoclonic-atonic seizures. However, in many cases the cause remains unknown. Epilepsy with myoclonic-atonic seizures can be inherited from an affected parent or occur for the first time in a family as a sporadic disease.
What are the alternative names for Epilepsy with Myoclonic-Atonic Seizures?
  • Epilepsy with myoclonic-atonic seizures
  • Doose syndrome
  • Epilepsy with myoclonic-astatic seizures
  • Epilepsy with myoclono-astatic crisis
  • Myoclonic astatic epilepsy
Who are the top Epilepsy with Myoclonic-Atonic Seizures Local Doctors?
Experienced in Epilepsy with Myoclonic-Atonic Seizures
Dr. Jeffrey L. Shy
Neurology
Experienced in Epilepsy with Myoclonic-Atonic Seizures
Dr. Jeffrey L. Shy
Neurology
726 N Greenfield Rd, Suite 110, 
Gilbert, AZ 
 (2.9 mi)
480-834-8885
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Shy is a Neurologist in Gilbert, Arizona. Dr. Shy and is rated as an Experienced provider by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. His top areas of expertise are Memory Loss, Lewy Body Dementia (LBD), Cerebellar Degeneration, and Autosomal Dominant Partial Epilepsy with Auditory Features. Dr. Shy is currently accepting new patients.

Experienced in Epilepsy with Myoclonic-Atonic Seizures
Dr. Farrukh Qureshi
Neurosurgery | Neurology
Experienced in Epilepsy with Myoclonic-Atonic Seizures
Dr. Farrukh Qureshi
Neurosurgery | Neurology

Phoenix Neurological Institute, Inc

1343 N Alma School Rd, Suite 125 135 295, 
Chandler, AZ 
 (4.4 mi)
480-776-2982
Languages Spoken:
English, Hindi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Farrukh Qureshi is a Neurosurgery specialist and a Neurologist in Chandler, Arizona. Dr. Qureshi and is rated as an Experienced provider by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. His top areas of expertise are Obstructive Sleep Apnea, Memory Loss, Epilepsy in Children, and Infant Epilepsy with Migrant Focal Crisis. Dr. Qureshi is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Epilepsy with Myoclonic-Atonic Seizures
Dr. Kerry M. Amstutz
Family Medicine
Experienced in Epilepsy with Myoclonic-Atonic Seizures
Dr. Kerry M. Amstutz
Family Medicine

Bhsm Rehabilitation LLC

1255 W Baseline Rd, 
Mesa, AZ 
 (4.5 mi)
480-820-7675
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kerry Amstutz is a Family Medicine provider in Mesa, Arizona. Dr. Amstutz and is rated as an Experienced provider by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. His top areas of expertise are Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and Epilepsy with Myoclonic-Atonic Seizures. Dr. Amstutz is currently accepting new patients.

View All Doctors
What are the latest Epilepsy with Myoclonic-Atonic Seizures Clinical Trials?
Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Enrollment Status: Recruiting
Publish Date: February 12, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: The primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.

Match to trials
Find the right clinical trials for you in under a minute
Get started
CureDRPLA Global Patient Registry for Individuals With Dentatorubral-pallidoluysian Atrophy (DRPLA)
CureDRPLA Global Patient Registry for Individuals With Dentatorubral-pallidoluysian Atrophy (DRPLA)
Enrollment Status: Recruiting
Publish Date: February 11, 2025

Summary: The objective of the CureDRPLA Global Patient Registry is to establish a longitudinal database of patient-reported data on individuals affected with Dentatorubral-pallidoluysian atrophy (DRPLA) from anywhere in the world. The CureDRPLA Global Patient Registry will address patient needs by: * Expanding patient engagement by documenting quality of life outcomes. * Providing anonymized data to the DR...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center